Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15778975 | 0.87 | KDM5A (0.45) | NPC1RAB9ASMN1; SMN2HPGDNFKB1 | |
| SCHEMBL10088945 | 0.85 | TTR (0.43) | SMN1; SMN2MAPTHSD17B10HTTMRGPRX4 | |
| Hydrochloric Acid SCHEMBL15350295 | 0.82 | CSNK2A1 (0.60) | SMN1; SMN2MAPTHSD17B10MRGPRX4PPARA | |
| SCHEMBL16650844 | 0.81 | KDM4E (0.43) | NPC1RAB9ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL16616052 | 0.81 | KIF11 (0.42) | MAPTHSD17B10TTRMEN1KMT2A | |
| SCHEMBL10088933 | 0.81 | S1PR1 (0.44) | MAPTHSD17B10MRGPRX4MEN1KMT2A | |
| SCHEMBL17159721 | 0.81 | GLA (0.41) | SMN1; SMN2MAPTHSD17B10MRGPRX4PPARA | |
| SCHEMBL15351230 | 0.80 | MRGPRX4 (0.43) | MAPTHSD17B10MRGPRX4MEN1KMT2A | |
| SCHEMBL3083420 | 0.79 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2HPGDNFKB1 | |
| SCHEMBL22000046 | 0.79 | TDP1 (0.51) | MAPTHSD17B10MRGPRX4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944634-B2 | Pyrazolopyridine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2018-04-17 | — | — | US | disclosed |
| EP-2914597-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2841435-B1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2017-09-06 | — | — | EP | disclosed |
| CN-104812755-B | It is used as the pyrazolo pyridine derivatives of TTX S blocking agents | 拉夸里亚创药株式会社 | 2017-08-08 | — | — | CN | disclosed |
| CN-104520296-B | Pyrrolopyridinone derivatives as TTX-S blocker | 拉夸里亚创药株式会社 | 2016-11-16 | — | — | CN | disclosed |
| EP-2354134-B1 | 2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR | ASTELLAS PHARMA INC (JP) | 2016-02-24 | — | — | EP | disclosed |
| US-9187475-B2 | Pyrrolopyridinone derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150291582-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-2914597-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2015-09-09 | — | — | EP | disclosed |
| CN-104520296-A | Pyrrolopyridinone derivatives as TTX-S blockers | RAQUALIA PHARMA INC | 2015-04-15 | — | — | CN | disclosed |
| US-20150094306-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2015-04-02 | — | — | US | disclosed |
| EP-2841435-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RaQualia Pharma Inc (JP) | 2015-03-04 | — | — | EP | disclosed |
| WO-2014068988-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2014-05-08 | — | — | WO | disclosed |
| WO-2013161312-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2013-10-31 | — | — | WO | disclosed |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2354134-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | Astellas Pharma Inc. (JP) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010064707-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | アステラス製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094306-A1 | PYRROLOPYRIDINONE DERIVATIVES AS TTX-S BLOCKERS | SCN5A, SCN1B, SCN1A | NPC1 1346/4885RAB9A 2061/4885SMN1; SMN2 338/4885 |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | NPC1 372/4885RAB9A 3084/4885SMN1; SMN2 1254/4885 |
| US-20150291582-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS | SCN5A, KCNH2, CACNA1G | NPC1 1290/4885RAB9A 2048/4885SMN1; SMN2 372/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | NPC1 271/4885RAB9A 2932/4885SMN1; SMN2 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.